Dr Ali McBride Discusses the Role of Biosimilars in Oncology

At the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center and president of ACCC, discussed the role of biosimilars in oncology and how familiar oncologists and their teams are with them.

Related Videos

Related Content

Advertisement

February 24th 2025

Price Caps During Accelerated Approval Would Help Address Financial Toxicity for Patients, Jensen Says

AJMC Staff Chelsee J. Jensen, PharmD, BCPS

Health care institutions with large numbers of Medicare and Medicaid patients may be constrained from offering cancer therapies made available under the accelerated approval pathway.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

February 21st 2025

NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS

Rose McNulty

The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

February 20th 2025

First Insulin Aspart Biosimilar Receives FDA Approval

Cameron Santoro

Merilog (insulin-aspart-szjj) is the first rapid-acting insulin biosimilar to Novolog (insulin aspart) that is designated to improve glycemic control in adults and adolescents with type 2 diabetes.

February 20th 2025

Getting More Doctors to Record a Life-Saving Prostate Cancer Calculation

Mary Caffrey

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is often missed by doctors, impacting patient care.

Related Content

Advertisement

February 24th 2025

Price Caps During Accelerated Approval Would Help Address Financial Toxicity for Patients, Jensen Says

AJMC Staff Chelsee J. Jensen, PharmD, BCPS

Health care institutions with large numbers of Medicare and Medicaid patients may be constrained from offering cancer therapies made available under the accelerated approval pathway.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

February 21st 2025

NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS

Rose McNulty

The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

February 20th 2025

First Insulin Aspart Biosimilar Receives FDA Approval

Cameron Santoro

Merilog (insulin-aspart-szjj) is the first rapid-acting insulin biosimilar to Novolog (insulin aspart) that is designated to improve glycemic control in adults and adolescents with type 2 diabetes.

February 20th 2025

Getting More Doctors to Record a Life-Saving Prostate Cancer Calculation

Mary Caffrey

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is often missed by doctors, impacting patient care.